Saturday 17 October 2026
Export TNGX’s income statement to Excel — free account
Tango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 5.71% and free cash flow fell 4.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
22.04
0.66
−2.91%
Follow TNGX
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 1 | 3 | 2 | 4 |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | 0.69 | 2.95 | 1.27 | 2.52 | (1.01) | 9.88 |
P/S ratio |
— | — | 0.00 | 18.34 | 25.82 | 25.84 | 8.02 | 16.50 |
Altman Z″-Score (non-manufacturers) |
— | — | 1.76 | 6.42 | 2.48 | 1.76 | (1.74) | 5.58 |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | (1,027.12) | (40.20) | (22.71) | (34.36) | (9.21) | (34.63) |
Beneish M-Score |
— | — | — | 0.18 | 4.66 | — | — | — |
P/B ratio |
— | — | 1.51 | 1.97 | 2.57 | 3.73 | 1.69 | 2.97 |
Price to Tangible BV |
— | — | 1.51 | 1.97 | 2.57 | 3.73 | 1.69 | 2.97 |
EV/Sales |
— | — | 0.00 | 5.23 | 11.07 | 16.59 | 1.89 | 10.99 |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | 0.00 | (3.25) | (2.52) | (5.14) | (0.61) | (4.94) |
EV/FCF |
— | — | 0.00 | (3.16) | (2.36) | (5.07) | (0.60) | (4.90) |
Quick Ratio |
— | — | 4.70 | 11.99 | 6.64 | 7.35 | 6.76 | 15.85 |
Current Ratio |
— | — | 4.73 | 12.10 | 6.76 | 7.54 | 6.98 | 16.32 |
Net Debt/EBITDA |
— | — | 3.70 | 8.48 | 3.35 | 2.93 | 1.75 | 3.08 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.07 | 0.10 | 0.05 | 0.09 | 0.12 | 0.17 |
Operating CF/Net income |
— | — | (1.35) | 1.02 | 1.01 | 1.16 | 1.01 | 1.37 |
Capex/Depreciation |
— | — | (1.54) | (2.05) | (4.78) | 1.56 | 0.36 | 2.57 |
| — | — | (20.50%) | (30.38%) | (36.41%) | (40.49%) | (57.58%) | (37.23%) | |
| — | 0.00% | (50.15%) | (16.46%) | (23.10%) | (24.25%) | (36.24%) | (28.41%) | |
ROIC |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (2,661.91%) |
Return on Tangible Assets |
— | — | (33.20%) | (12.76%) | (32.72%) | (32.77%) | (55.15%) | (29.97%) |
Average Days of Receivables |
— | — | 95.35 | 19.71 | 29.36 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | — | 652.96% | 209.59% | 426.01% | 315.38% | 342.10% | 211.86% |
Selling, General and Administrative Expense of Revenue |
— | — | 128.85% | 47.50% | 120.78% | 97.19% | 103.99% | 66.54% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 23.04% | 21.15% | 57.24% | 52.23% | 68.69% | 42.37% |
Graham Net Nets |
— | — | (0.02) | 0.50 | 0.29 | 0.21 | 0.44 | 0.29 |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | 0.00% | (8.58%) | (16.83%) | (11.02%) | (39.16%) | (9.71%) |
Free Cash Flow Yield |
— | — | 0.00% | (9.03%) | (18.19%) | (12.66%) | (39.19%) | (13.60%) |
Revenue per Share |
— | — | 0.24 | 0.60 | 0.28 | 0.39 | 0.39 | 0.54 |
Operating CF per Share |
— | — | 2.19 | (0.96) | (1.24) | (1.25) | (1.20) | (1.20) |
Capex per Share |
— | — | (0.03) | (0.03) | (0.09) | (0.02) | (0.01) | (0.01) |
Free Cash Flow per Share |
— | — | 2.16 | (0.99) | (1.33) | (1.26) | (1.21) | (1.20) |
Cash per Share |
— | — | 5.96 | 7.82 | 4.18 | 3.57 | 2.36 | 2.96 |
Shareholders Equity per Share |
— | — | 1.21 | 5.55 | 2.84 | 2.68 | 1.83 | 2.98 |
Interest Debt per Share |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | — | 1.21 | 5.55 | 2.84 | 2.68 | 1.83 | 2.98 |
Free Cash Flow |
— | — | 68.97 | (61.36) | (116.77) | (119.51) | (132.25) | (139.93) |
Working Capital |
— | — | 152.72 | 451.65 | 319.73 | 300.60 | 228.17 | 332.08 |
Capital Expenditures |
— | — | (1.11) | (1.84) | (7.69) | (1.53) | (0.75) | (1.05) |
Net Current Asset Value |
— | — | 24.98 | 336.93 | 188.28 | 197.08 | 149.37 | 301.25 |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.14 | 0.05 | 0.31 | 0.04 | 0.02 | 0.02 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | — | 0.19 | 0.19 | 0.15 | (0.10) | (0.26) | (0.06) |
Cash ROIC |
— | — | 30.13% | (7.39%) | (18.95%) | (20.23%) | (28.91%) | (20.29%) |
Accounts Receivable Turnover |
— | — | 3.83 | 18.52 | 12.43 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | 2.00 | 2.00 | 2.00 | — | — | — |
Average Payables |
— | — | 2.53 | 2.53 | 3.84 | 3.62 | 2.19 | 1.39 |
Average Assets |
— | 0.00 | 103.63 | 353.70 | 468.31 | 419.52 | 359.53 | 357.59 |
Average Common Equity |
— | — | 253.55 | 191.67 | 297.11 | 251.29 | 226.31 | 272.85 |
Columns are period end dates